|1.||Kawamura, Nanami: 5 articles (12/2013 - 08/2009)|
|2.||Kawamura, Kazuhiro: 5 articles (12/2013 - 08/2009)|
|3.||Tanaka, Toshinobu: 3 articles (03/2011 - 08/2009)|
|4.||Manabe, Motomu: 2 articles (12/2013 - 07/2010)|
|5.||Fujimoto, Toshio: 2 articles (01/2012 - 03/2011)|
|6.||Sato, Wataru: 2 articles (01/2012 - 08/2009)|
|7.||Kumagai, Jin: 2 articles (03/2011 - 08/2009)|
|8.||Winston, John H: 2 articles (01/2010 - 08/2003)|
|9.||Wang, Zun-Yi: 2 articles (07/2008 - 01/2006)|
|10.||Bjorling, Dale E: 2 articles (07/2008 - 01/2006)|
07/25/2002 - "These observations suggest that K252a derivatives, which are active in vivo as anti-cancer drugs in models of Trk-driven malignancies, should also be effective for treatment of Met-mediated tumors."
09/01/2013 - "These results suggest that k252a has potential for tumor regression and relapse prevention in LCNEC. "
01/01/1999 - "K252a is a useful tool for studying the effects of CDK inhibition and cell cycle blockade in tumor cells."
09/01/1996 - "Hence, K252a inhibition of Trk phosphorylation most probably contributed, in part, to the inhibition of prostate tumor cell growth in vitro. "
12/01/2013 - "Treatment with K252a inhibited metastasis of tumors to distant organs. "
|2.||Brain Injuries (Brain Injury)
01/01/2005 - "The neuroprotective effects of K252a through inhibiting MLK3/MKK7/JNK3 signaling pathway on ischemic brain injury in rat hippocampal CA1 region."
05/01/2015 - "In turn, intrahippocampal injections of K252a, a TrkB antagonist, counteracted the 7,8-DHF induced TrkB signaling activation and memory improvement in TBI, suggesting the pivotal role of TrkB signaling in cognitive performance after brain injury. "
|3.||Endometrial Neoplasms (Endometrial Cancer)
03/01/2008 - "K252a is highly effective in suppressing the growth of human endometrial cancer cells, but has little effect on normal human endometrial epithelial cells."
03/01/2008 - "These results raise the possibility that K252a may prove to be particularly effective in the treatment of endometrial cancers."
03/01/2008 - "Endometrial cancer cells were treated with K252a and its effect on cell growth, cell cycle and related measurements was assessed. "
03/01/2008 - "To elucidate the involvement of K252a in endometrial cancer, we investigated the effects of K252a on three endometrial cancer cell lines. "
03/01/2008 - "3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays showed that the endometrial cancer cell lines were sensitive to the growth inhibitory effect of K252a, although normal endometrial epithelial cells were viable after treatment with the same doses of K252a that induced the growth inhibition of endometrial cancer cells. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
07/01/2005 - "These results raise the possibility that K252a may prove particularly effective in treatment of ovarian cancer."
07/01/2005 - "MTT assays showed that the ovarian cancer cell line SK-OV-3 cells were sensitive to the growth inhibitory effect of K252a. "
07/01/2005 - "To elucidate the involvement of K252a in ovarian cancer, we investigated the effects of K252a on the ovarian cancer cell line, SK-OV-3. "
07/01/2005 - "K252a inhibits proliferation of ovarian cancer cells by upregulating p21WAF1."
|2.||Adenosine Triphosphate (ATP)
|3.||Nerve Growth Factor (NGF)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|5.||Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)
|6.||Caspase 3 (Caspase-3)
|8.||Brain-Derived Neurotrophic Factor (BDNF)
|9.||Protein Kinase Inhibitors
|10.||Chorionic Gonadotropin (Human Chorionic Gonadotropin)
|2.||Heterologous Transplantation (Xenotransplantation)